Invasive pulmonary aspergillosis with hematological malignancy caused by Aspergillus terreus and in vitro susceptibility of A. terreus isolate to micafungin

Internal Medicine

Volumn 46, Issue 11, 2007, Pages 775-780

  Tokimatsu, Issei ^a   Kushima, Hisako ^a   Iwata, Atsuko ^a   Hashinaga, Kazuhiko ^a   Umeki, Kenji ^a   Ohama, Minoru ^a   Kohno, Kazuhiro ^a   Ishii, Hiroshi ^a   Kishi, Kenji ^a   Ogata, Masao ^a   Hiramatsu, Kazufumi ^a   Saikawa, Tetsunori ^b   Kadota, Jun Ichi ^a  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Amphotericin B (AMPH); Aspergillus terreus; Invasive pulmonary aspergillosis (IPA); Micafungin (MCFG); Time kill assay

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; HYDROXYUREA; IMATINIB; ITRACONAZOLE; MICAFUNGIN;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS TERREUS; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DEATH; DISEASE SEVERITY; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; GRAFT FAILURE; HEMATOLOGIC MALIGNANCY; HEMOPTYSIS; HUMAN; IN VITRO STUDY; LUNG ASPERGILLOSIS; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; SPUTUM ANALYSIS; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DRUG THERAPY, COMBINATION; HUMANS; ITRACONAZOLE; LEUKEMIA, MYELOID, CHRONIC; LIPOPROTEINS; LUNG DISEASES, FUNGAL; MALE; NEUTROPENIA; OPPORTUNISTIC INFECTIONS; PEPTIDES, CYCLIC; SPUTUM; STEM CELL TRANSPLANTATION;

EID: 34250176201     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6193     Document Type: Article

References (17)

1. Lin SJ, Schranz J, Teutsh SM. Aspergillosis care-fatality rate: systemic review of the literature. Clin Infect Dis 32: 358-366, 2001.
2. Rinaldi MG. Invasive aspergillosis. Rev Infect Dis 5: 1061-1077, 1983.
3. Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant amphotericin B. J Infect Dis 188: 305-319, 2003.
4. Baddley JW, Pappas PG, Smith AC, Moser SA. Epidemiology of Aspergillus terreus at a university hospital. J Clin Microbiol 41: 5525-5529, 2003.
5. Lass-Florl C, Rath PM, Niederwieser D. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hospital Infection 46: 31-35, 2000.
6. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre, experience. Br J Haematol 131: 201-207, 2005.
7. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 41: 3623-3626, 2003.
8. Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 48: 3217-3225, 2004.
9. Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin (FK 463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 51: 913-919, 2003.
10. Barchiesi F, Spreghini E, Santinelli A, et al. Efficacy of caspo-fungin against Aspergillus terreus. Antimicrob Agents Chemoter 49: 5133-5135, 2005.
11. Steinbach WJ, Benjamin DK, Kotoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 39: 192-198, 2004.
12. Hachem RY, Kontoyiannis DP, Boktour MR, et al. Aspergillus terreus: an emerging amphotencin B-resistant opportunistic mold in patients with hematologic malignancies. Cancer 101: 1594-600, 2004.
13. National Committee for Clinical Laboratory Standards. Reference method for broth dilution andfungal susceptibility testing of conidium-forming filamenous fungi; proposed standard. Document M-38P. National Committee for Clinical Laboratory Standards, Wayne, PA, 1998.
14. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis 33: 1824-1833, 2001.
15. Gomez-Lopez A, Garcia-Effron G, Mellado E, et al. In vitro activities of three licenced antifungal agents against Spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 47: 3085-3088, 2003.
16. Albelda SM, Talbot GH, Gerson SL, et al. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Am Rev Respir Dis 131: 115-120, 1985.
17. Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother 37: 778-784, 1993.